Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany. - Hoechstetter MA; Knauf W; Dambacher S; Hucke N; Höhne K; van Troostenburg A; Ramroth H; Abenhardt W; Rummel M (Clinical lymphoma, myeloma & leukemia, 2022)